Novel Alzheimer’s drug candidates
2020
Georg-August University, Göttingen, Germany
The human zinc(II) enzyme glutaminyl cyclase (QC) is suggested to participate in the pathogenesis of Alzheimer’s disease. Using protein crystallography and X-ray structure analyses the authors show snapshots of QC structure and identify hydrazides as highly selective QC inhibitors. Thus, the authors envision a putative use for hydrazydes in Alzheimer's disease, as well as in Huntington's disease and various cancers.
Hydrazides are potent transition-state analogues for glutaminyl cyclase implicated in the pathogenesis of Alzheimer’s disease
Kai Tittmann
Added on: 07-22-2020
[1] https://pubs.acs.org/doi/full/10.1021/acs.biochem.0c00337[2] https://www.bionity.com/en/news/1167267/a-chemical-tailor-made-suit-for-alzheimers-drugs.html?pk_campaign=ca0264&WT.mc_id=ca0264
